Sale of Oculo, CERA’s first spin-out company
Oculo, the first spin-out company to be incubated at the Centre for Eye Research Australia, has been sold to Finnish ophthalmic diagnostics company Revenio.
Oculo was incubated at CERA by former Managing Director Professor Jonathan Crowston and Dr Kate Taylor before being spun out as a separate entity in 2015.
A teleophthalmology and clinical communication platform company, Oculo focuses on telehealth, remote monitoring and clinical communications.
The Oculo platform is designed to share clinical imaging, referrals, and other clinical correspondence securely and instantly between health care professionals.
It now has a user base of over seven out of 10 eye care providers in Australia and New Zealand, has managed over a million patients and is the partner for KeepSight.
Current CERA Managing Director Professor Keith Martin says a major part of CERA’s mission is to develop new technologies to improve eye health.
“We are so proud that Oculo, our first spin-out company, is having such success in revolutionising communication between eye care professionals,’’ he says.
“Now, with Revenio’s strategy and support, we look forward to seeing even greater impact in the future.”
Professor Martin says the success of Oculo highlights the positive impact of commercialising promising research findings, enabling them to be translated into clinical practice to benefit patients.
He says CERA actively encourages its researchers to innovate and accelerate the progress of new treatments and technologies from the lab to the eye clinic.
More recently, CERA supported the incubation of the spin-out company Enlighten Imaging, which is developing a simple eye test to detect the early signs of Alzheimer’s disease.